Pay in 4 interest-free payments of $9.75 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
22(5):1026-34
half-life (2
It demonstrates >100-fold selectivity for PKM2 over the related PKM1
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
Currently GSK2879552 is in phase I clinical trials targeting Acute Myeloid Leukemia (AML) and Relapsed/Refractory Small Cell Lung Carcinoma
LDN-57444 - Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) Inhibitor. CAS# 668467-91-2 Catalog No.:M60204-10S 22(5):1026-34LDN 57444, CAS No. 668467 91 2, is a novel potent and selective inhibitor of ubiquitin C terminal hydrolase L1 (UCH L1) with IC50 ~0. 88 M. It has ~28 fold greater selectivity over UCH L3 (ubiquitin C terminal hydrolase L3). LDN 57444 can increase levels of highly ubiquitinated proteins and decreases ubiquitin proteasome activity. It causes cell death through the apoptosis pathway. LDN 57444s activity leads to dramatic alterations in synaptic protein